Sequence Your Cancer
without a biopsy
Break free from outdated biopsies and stay ahead of cancer by tracking it genetically in real-time - all from a simple blood test.
This changes everything.
Track cancer in real time with GUARDANT360 and break free from biopsies
GUARDANT360 is a breakthrough test that enables comprehensive sequencing of tumor DNA using a simple blood test without the need of a risky, costly and invasive biopsy.
‣ Genetic resistance mutations often emerge in patients with advanced cancers or after a couple of cycles of treatment.
‣ Relapse or therapeutic failure is often caused by these resistance mutations
‣ These mutations are often not present in the original biopsy
‣ Many of these mutations are actionable if detected
Which cancer do you want to treat: that at initial diagnosis or your cancer now?
Most biopsy-based tumor sequencing or genetic profiling approaches employ a "once and for all" philosophy implying that your cancer at initial diagnosis or last biopsy is similar to your cancer now. In contrast, GUARDANT360 sequences your current cancer and is able to detect resistance mutations and other genomic alterations that may not have been present at the time of your biopsy.
Break free from biopsies in 4 easy steps:
Your physician collects a tube of blood and places the order.
We reconstruct and sequence your current cancer using tumor-derived DNA in your blood.
We generate a simple report of actionable genetic alterations with associated treatments.
Your physician can use the report to personalize your treatment options for your unique cancer.
Why is real-time cancer sequencing critical?
What the Medical Community is saying about GUARDANT360
I’m very excited that the power of non-invasive tumor sequencing will soon be available to all cancer patients through GUARDANT360.
Dr. Dave S. Hoon
John Wayne Medical Center
Interested in learning more?
GUARDANT360 has undergone clinical validation in collaboration with leading cancer centers in the United States and abroad and is being used for companion diagnostics in clinical studies of molecularly targeted drug therapies. If you are a patient or medical professional interested in additional information or applying for early access to the test please click the appropriate button below:
Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and rare-cell diagnostics and is closely advised by an oncologist-led medical steering committee from leading cancer centers across North America and abroad.
© 2014 GUARDANT HEALTH, INC. ALL RIGHTS RESERVED.
Legal / Privacy